Protection of non-human primates against rabies with an adenovirus recombinant vaccine
- The Wistar Institute of Anatomy and Biology, Philadelphia, PA (United States)
- Centers for Disease Control and Prevention, Atlanta, GA (United States)
- The Global Alliance for Rabies Control, Manhattan, KS (United States)
Rabies remains a major neglected global zoonosis. New vaccine strategies are needed for human rabies prophylaxis. A single intramuscular immunization with a moderate dose of an experimental chimpanzee adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein, resulted in sustained titers of rabies virus neutralizing antibodies and protection against a lethal rabies virus challenge infection in a non-human primate model. Taken together, these data demonstrate the safety, immunogenicity, and efficacy of the recombinant Ad-rabies vector for further consideration in human clinical trials. - Highlights: • Pre-exposure vaccination with vaccine based on a chimpanzee derived adenovirus protects against rabies. • Protection is sustained. • Protection is achieved with single low-dose of vaccine given intramuscularly. • Protection is not affected by pre-existing antibodies to common human serotypes of adenovirus.
- OSTI ID:
- 22435016
- Journal Information:
- Virology, Journal Name: Virology Vol. 450-451; ISSN VIRLAX; ISSN 0042-6822
- Country of Publication:
- United States
- Language:
- English
Similar Records
A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice
Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine
Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors
Journal Article
·
Tue Dec 19 23:00:00 EST 2006
· Virology
·
OSTI ID:20850581
Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine
Journal Article
·
Fri Oct 12 20:00:00 EDT 2018
· Vaccine
·
OSTI ID:1494688
Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors
Journal Article
·
Tue Nov 18 19:00:00 EST 2014
· Journal of Virology
·
OSTI ID:1235731